Acceleron Reports Second Quarter 2018 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acceleron Pharma (XLRN) Tops Q2 EPS by 1c
August 2, 2018 4:15 PM EDTAcceleron Pharma (NASDAQ: XLRN) reported Q2 EPS of ($0.63), $0.01 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $3.8 million.
MEDALIST and BELIEVE Phase 3 trials met all primary and key secondary endpoints
ACE-083 Part 2 of the Phase 2... More
